Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRESSA vs docetaxel in previously platinum-treated advanced non-small cell lung cancer
2004-002943-28Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Overall survival. Started Nov 2004; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-002943-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002943-28.